ESC Professional Premium Access

The DPP4 inhibitor linagliptin exacerbated heart failure due to energy deficiency via downregulation of glucose absorption and utilization in mice.

Congress Presentation

About the speaker

Doctor Aya Shiraki

Saga University, Saga (Japan)
0 follower

5 more presentations in this session

Empagliflozin rescues primary murine cardiac fibroblasts, but not cardiomyocytes, from hypoxia-reoxygenation injury through STAT3-mediated cascades.

Speaker: Mrs P. Nikolaou (Athens, GR)

Thumbnail

Anti-inflammatory potential of SGLT2 inhibitors: a systematic review and meta-analysis of preclinical studies in rodents

Speaker: Doctor M. Sagris (Athens, GR)

Thumbnail

Four-months treatment with dapagliflozin improves endothelial glycocalyx and cardiovascular function in patients with type 1 diabetes mellitus.

Speaker: Doctor I. Ikonomidis (Athens, GR)

Thumbnail

Absolute treatment effects for the primary outcome and all-cause mortality in the cardiovascular outcome trials in type 2 diabetes: a meta-analysis of individual patient data

Speaker: Mr G. Wolff (Duesseldorf, DE)

Thumbnail

Adherence and discontinuation of sglt2-inhibitors and glp1-r agonists in patients with type 2 diabetes with and without cardiovascular disease

Speaker: Doctor M. Malik (Copenhagen, DK) Doctor A. Falkentoft (Roskilde, DK)

Thumbnail

Access the full session

Anti-diabetic pharmacotherapy in clinical practice

Speakers: Doctor A. Shiraki, Mrs P. Nikolaou, Doctor M. Sagris, Doctor I. Ikonomidis, Mr G. Wolff...
Thumbnail

About the event

Image

ESC Congress 2022

26 August - 29 August 2022

Sessions Presentations

ESC 365 is supported by

logo Novo Nordisk